Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 26, 2024

Long-Term Outcomes After Lorlatinib vs Crizotinib in Patients With Advanced ALK-Positive NSCLC

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
J. Clin. Oncol 2024 May 31;[EPub Ahead of Print], BJ Solomon, G Liu, E Felip, TSK Mok, RA Soo, J Mazieres, AT Shaw, F de Marinis, Y Goto, YL Wu, DW Kim, JF Martini, R Messina, J Paolini, A Polli, D Thomaidou, F Toffalorio, TM Bauer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading